The Seattle Heart Failure Model
Wayne C. Levy(Pfizer (United States)), Milton Packer(Baylor University Medical Center), Santosh Sutradhar(Pfizer (United States)), David T. Linker(Pfizer (United States)), Paul Burton(Newcastle University), Bertram Pitt(Bayer (Germany)), Dariush Mozaffarian(Tufts University), Mark D. Sullivan(University of Northern Virginia), Douglas L. Mann(Washington University in St. Louis), Aldo P. Maggioni(Health Care Foundation), Philip A. Poole‐Wilson(Mario Negri Institute for Pharmacological Research), Stefan D. Anker(Bayer (Germany)), Anne B. Cropp(Pfizer (United States)), Inder S. Anand(University of Minnesota)
Cited by 2,023
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k